vesemnogene lantuparvovec

N/A

Report date: 2025/12/05 20:00:50

Base Information

Drug Namevesemnogene lantuparvovec
Drug Alias NameAAV-hSMN1
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionSMN gene transference
TargetsSurvival motor neuron protein
Therapy Area/IndicationsMuscular Atrophy, Spinal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndonesiaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLantu Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesLantu Biopharma Inc
Inactive CompaniesN/A
Active IndicationsMuscular Atrophy, Spinal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A